Antiviral Treatment and One-Year Follow-Up of Chronic Hepatitis B Patients in Bandung: An Observational Study

Background: Hepatitis B Virus (HBV) is a health problem that has chronically infected 257 million globally. Appropriate therapy immensely needed to prevent disease progression cirrhosis and hepatocellular carcinoma (HCC). Moreover, routine monitoring required assess the efficacy of given treatment. This study aims describe treatment its follow-up outcomes among chronic HBV patients after one year in Bandung.Method: was cross-sectional descriptive with data sampling method obtained from assessing medical records treated outpatients at Gastrohepatoenterology Clinic Hasan Sadikin Hospital Bandung 2018 2020. Laboratory findings before were further assessed.Results: Out 107 treated, proportion tenofovir 72.90%, telbivudine 16.80%, lamivudine 8.40%, interferon group 1.90%. There 52.30% who did visits therapy. The therapeutic outcome rate evaluated total criteria decreasing AST (91.18%) ALT levels (93.10%) levels, reduction HBV-DNA values (100%), HBeAg seroconversion (14.29%).Conclusion: most tenofovir. 52.30%. Overall, antiviral therapies produced decreases liver laboratory parameters, HBV-DNA, HBeAg.